As regards mAbs, Alirocumab, used to control dyslipidemia, alleviated hippocampal LRP1 expression levels and by this way modulated brain cholesterol homeostasis, reduced hippocampal BACE1 and Aβ42, and restrained cognitive impairment in high cholesterol-fed AD-like rats [190]. This evidence concerns the gene BACE1 and Alzheimer disease.